Docetaxel oral - Athenex

Drug Profile

Docetaxel oral - Athenex

Alternative Names: Docetaxel + HM-30181A; Oradoxel; Oral docetaxel - Athenex

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Athenex
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer
  • Preclinical Cancer

Most Recent Events

  • 15 Mar 2017 Phase-I clinical trials in Prostate cancer (Metastatic disease) in New Zealand (PO) (ACTRN12616000983404)
  • 09 Nov 2016 Kinex Pharmaceuticals plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Monotherapy) in USA (PO) (NCT02963168)
  • 02 Aug 2016 Athenex plans a phase I trial for Prostate cancer (Metastatic disease) in New Zealand (ACTRN12616000983404)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top